Menu
Search
|

Menu

Close
X

Xenetic Biosciences Inc XBIO.OQ (NASDAQ Stock Exchange Capital Market)

2.02 USD
-0.07 (-3.35%)
As of 2:29 PM GMT
chart
Previous Close 2.09
Open 2.02
Volume 151
3m Avg Volume 3,122
Today’s High 2.02
Today’s Low 2.02
52 Week High 5.90
52 Week Low 1.75
Shares Outstanding (mil) 8.72
Market Capitalization (mil) 25.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
3
FY15
0
EPS (USD)
FY17
-0.930
FY16
-7.706
FY15
-2.936
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.63
5.77
Price to Book (MRQ)
vs sector
2.25
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-72.68
14.43
Return on Equity (TTM)
vs sector
-141.57
16.13

EXECUTIVE LEADERSHIP

Jeffrey Eisenberg
Chief Executive Officer, Chief Operating Officer, Director, Since 2017
Salary: --
Bonus: --
James Parslow
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Curtis Lockshin
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
Colin Hill
Treasurer, Secretary, Director, Since 2017
Salary: $253,133.00
Bonus: --
Timothy Cote
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 230
LEXINGTON   MA   02421-7998

Phone: +1781.7787720

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.

SPONSORED STORIES